Search

Your search keyword '"Viennot, S."' showing total 167 results
Start Over Author "Viennot, S."
167 results on '"Viennot, S."'

3. P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial

Author

Vuitton, L, primary, Poullenot, F, additional, Bouhnik, Y, additional, Wils, P, additional, Buisson, A, additional, Viennot, S, additional, Bouguen, G, additional, Hébuterne, X, additional, Gilletta, C, additional, Nancey, S, additional, Bourreille, A, additional, Amil, M, additional, Altwegg, R, additional, Goutorbe, F, additional, Caillo, L, additional, Plastaras, L, additional, Brixi, H, additional, Simon, M, additional, Serrero, M, additional, Fumery, M, additional, Rahier, J F, additional, Vicaut, E, additional, and Peyrin-Biroulet, L, additional

Published
2024
Full Text
View/download PDF

4. DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort

Author

Reenaers Dr, C, primary, Enea, D, additional, Nachury, M, additional, Laharie, D, additional, Bouhnik, Y, additional, Fumery, M, additional, Gornet, J M, additional, Amiot, A, additional, Altwegg, R, additional, de Vos, M, additional, Marteau, P, additional, Bourreille, A, additional, Nancey, S, additional, Viennot, S, additional, Louis, E, additional, and svrcek, M, additional

Published
2024
Full Text
View/download PDF

5. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

Author

Debinski, H., Florin, T., Hetzel, D., Lawrance, I., Radford-Smith, G., Sloss, A., Sorrentino, D., Gassner, S., Haas, T., Reicht, G., Reinisch, W., Strasser, M., Vogelsang, H., Bossuyt, P., DeWit, O., D'Haens, G., Franchimont, D., Louis, E., Vermeire, S., Bernstein, C.N., Bourdages, R., Chiba, N., Dhalla, S.S., Feagan, B.G., Fedorak, R.N., Lachance, J.R., Panaccione, R., Ropeleski, M., Singh Salh, B., Lukas, M, Colombel, J-F, Allez, M., Desreumaux, P., Dupas, J.L., Grimaud, J-C., Hebuterne, X., Laharie, D., Lerebours, E., Peyrin-Biroulet, L., Reimund, J-M., Viennot, S., Zerbib, F., Antoni, C., Atreya, R., Baumgart, D.C., Berg, C., Boecker, U., Bramkamp, G., Bünning, C., Ehehalt, R., Howaldt, S., Kucharzik, T., Lamprecht, H.G., Mudter, J., Preiss, J.C., Schreiber, S., Seidler, U., Altorjay, I., Banai, J., Lakatos, P.L., Varga, M., Vincze, A., Avni-Biron, I., Fishman, S., Fraser, G.M., Goldin, E., Rachmilewitz, D., Annese, V., Ardizzone, S., Biancone, L., Bossa, F., Danese, S., Fries, W., Gionchetti, P., Maconi, G., Terrosu, G., Usai, P., D'Haens, G.R., Gearry, R.B., Hill, J., Rowbotham, D.S., Schultz, M., Stubbs, R.S., Wallace, D., Walmsley, R.S., Wyeth, J., Malecka-Panas, E., Paradowski, L., Regula, J., Beales, I.P., Campbell, S., Hawthorne, A.B., Parkes, M., Travis, S.P., Achkar, J.P., Behm, B.W., Bickston, S.J., Brown, K.J., Chiorean, M.V., DeVilliers, W.J.S., Elliott, D.E., Grunkmeier, D., Hamilton, J.W., Hanauer, S.B., Hanson, J.S., Hardi, R., Helper, D.J., Herfarth, H., Higgins, P.D.R., Holderman, W.H., Kottoor, R., Kreines, M.D., Leman, B.I., Li, X., Loftus, E.V., Jr., Noar, M., Oikonomou, I., Onken, J., Peterson, K.A., Phillips, R.P., Randall, C.W., Ricci, M., Ritter, T., Rubin, D.T., Safdi, M., Sandborn, W.J., Sauberman, L., Scherl, E., Schwarz, R.P., Sedghi, S., Shafran, I., Sninsky, C.A., Stein, I., Swoger, J., Vecchio, J., Weinberg, D.I., Wruble, L.D., Yajnik, V., Younes, Z., Regueiro, Miguel, Feagan, Brian G., Zou, Bin, Johanns, Jewel, Blank, Marion A., Chevrier, Marc, Plevy, Scott, Popp, John, Cornillie, Freddy J., Lukas, Milan, Danese, Silvio, Gionchetti, Paolo, Hanauer, Stephen B., Reinisch, Walter, Sandborn, William J., Sorrentino, Dario, and Rutgeerts, Paul

Published
2016
Full Text
View/download PDF

8. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

Author

Tadbiri, S., Peyrin‐Biroulet, L., Serrero, M., Filippi, J., Pariente, B., Roblin, X., Buisson, A., Stefanescu, C., Trang‐Poisson, C., Altwegg, R., Marteau, P., Vaysse, T., Bourrier, A., Nancey, S., Laharie, D., Allez, M., Savoye, G., Gilletta, C., Gagniere, C., Vuitton, L., Viennot, S., Aubourg, A., Pelletier, A.‐L., Bouguen, G., Abitbol, V., Fumery, M., Claudepierre, P., Bouhnik, Y., Amiot, A., Amiot, Aurelien, Gagniere, Charlotte, Serrero, Melanie, Grimaud, Jean‐Charles, Peyrin‐Biroulet, Laurent, Zallot, Camille, Bigard, Marc‐Andre, Filippi, Jerome, Hebuterne, Xavier, Pariente, Benjamin, Nachury, Maria, Desreumaux, Pierre, Roblin, Xavier, Del Tedesco, Emilie, Buisson, Anthony, Bommelaer, Gilles, Stefanescu, Carmen, Bouhnik, Yoram, Boureille, Arnaud, Trang‐Poisson, Caroline, Altwegg, Romain, Marteau, Philippe, Dray, Xavier, Carbonnel, Franck, Vaysse, Thibaud, Seksik, Philippe, Beaugerie, Laurent, Cosnes, Jacques, Sokol, Harry, Landman, Cecilia, Bourrier, Anne, Nancey, Stephane, Boschetti, Gilles, Laharie, David, Poullenot, Florian, Allez, Matthieu, Gornet, Jean‐Marc, Baudry, Clautilde, Savoye, Guillaume, Moreau, Jacques, Vuitton, Lucine, Koch, Stephane, Viennot, Stephanie, Aubourg, Alexandre, Picon, Laurence, Pelletier, Anne‐Laure, Sickersen, Gaelle, Bouguen, Guillaume, Abitbol, Vered, Chaussade, Stanislas, Fumery, Mathurin, Nahon, Stephane, Winkfield, Betsy, Brixi‐benmansour, Hedia, Gincul, Rodica, Barberis, Jean‐Christophe, Bonaz, Bruno, Michiels, Christophe, Zerbib, Franck, Bourrier de Beauregard, Marie, Locher, Christophe, Davin‐Couve, Sophie, Poirette, Armelle, Guillem, Laurence, Stetiu‐Mocanu, Monica, Philippe, Beau, Beorchia, Sylvain, and Al Qaddi, Jawad

Published
2018
Full Text
View/download PDF

9. Efficacy and safety of golimumab in Crohnʼs disease: a French national retrospective study

Author

Martineau, C., Flourié, B., Wils, P., Vaysse, T., Altwegg, R., Buisson, A., Amiot, A., Pineton de Chambrun, G., Abitbol, V., Fumery, M., Hébuterne, X., Viennot, S., Laharie, D., Beaugerie, L., Nancey, S., Sokol, H., Abitbol, Vered, Altwegg, Romain, Amiot, Aurélien, Beaugerie, Laurent, Boschetti, Gilles, Bourrier, Anne, Buisson, Anthony, Carbonnel, Frank, Condat, Joris, Cosnes, Jacques, Flourié, Bernard, Fumery, Mathurin, Hébuterne, Xavier, Kirchgesner, Julien, Laharie, David, Landman, Cécilia, Loreau, Julien, Marteau, Philippe, Martineau, Chloé, Mille, Fréderic, Nancey, Stéphane, Nion‐Larmurier, Isabelle, Pineton de Chambrun, Guillaume, Nachury, Maria, Pariente, Benjamin, Seksik, Philippe, Sokol, Harry, Vaysse, Thibaut, Viennot, Stéphanie, and Wils, Pauline

Published
2017
Full Text
View/download PDF

12. Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study

Author

Poullenot, F, primary, Amiot, A, additional, Nachury, M, additional, Viennot, S, additional, Altwegg, R, additional, Bouhnik, Y, additional, Abitbol, V, additional, Nancey, S, additional, Vuitton, L, additional, Peyrin-Biroulet, L, additional, Biron, A, additional, Fumery, M, additional, Picon, L, additional, Vidon, M, additional, Reenaers, C, additional, Serrero, M, additional, Savoye, G, additional, Beaugerie, L, additional, Rivière, P, additional, and Laharie, D, additional

Published
2022
Full Text
View/download PDF

13. Recommandations de pratique pour le diagnostic et la prise en charge de la rectocolite hémorragique

Author

Amiot, A., Viennot, S., Uzzan, M., Riviere, P., Cosquer, G.L., Yzet, C., Biron, A, Gilletta, C., Abitbol, V., Vuitton, L., Nachury, M., Simon, M., Remy, A.-J., Nahon, S., Faure, P., Guillo, L., Wils, P., Brixi, H., Bourrier, A., Serrero, M., Caillo, L., Bouguen, G., Laharie, D, Hôpital Bicêtre, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Henri Mondor, CHU Bordeaux [Bordeaux], CHU Amiens-Picardie, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Mutualiste de Montsouris (IMM), Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Pré, Pierre Cherest, Hartmann], CHU Marseille, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and CHU Pontchaillou [Rennes]

Subjects
[SDV]Life Sciences [q-bio], Inflammatory Bowel Disease, diagnostic, guidelines, ulcerative colites, traitement
Abstract

National audience; Background: Updating French clinical guidelines for diagnostic and management of ulcerative colitis is needed due to the emergence of new treatments and treatment goals. Methods: On behalf of the Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID), French clinical guidelines were updated through a validated process of adaptation of clinical guidelines from international Gastroenterology societies and French consensus meetings. Results: French clinical guidelines for the diagnostic and management of ulcerative colitis were drafted by 16 GETAID members and reviewed by 6 members of the GETAID, the Association Nationale des Hépato-gastroentérologues des Hôpitaux généraux (ANGH) and the Club de Réflexion des Cabinets et Groupes d'Hépato-Gastroentérologie (CREGG), graded according to the level of Evidence and the level of agreement by 68 experts from the latter three societies. The present guidelines focused on classification, diagnosis, histopathology, extra-intestinal manifestations, dysplasia and colorectal cancer, pouchitis, medical management of active disease and maintenance therapy.. Conclusion: This paper provides updated and useful guidelines for French gastroenterologists to diagnose and treat patients with ulcerative colitis. © John Libbey Eurotext, 2022.

Published
2022
Full Text
View/download PDF

14. P140 Immunomodulators are protective against severe COVID 19: results from a large multicentre cohort of inflammatory bowel disease patients

Author

Vuitton, L, primary, Bourrier, A, additional, Uzzan, M, additional, Nachury, M, additional, Amiot, A, additional, Roblin, X, additional, Allez, M, additional, Altwegg, R, additional, Vidon, M, additional, Bourreille, A, additional, Serrero, M, additional, Pelletier, A L, additional, Filippi, J, additional, Gilletta, C, additional, Simon, M, additional, Laharie, D, additional, Nahon, S, additional, Duveau, N, additional, Biron, A, additional, Viennot, S, additional, Abitbol, V, additional, Elgharabawy, Y, additional, and Peyrin-Biroulet, L, additional

Published
2022
Full Text
View/download PDF

15. P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents

Author

Lelong, M, primary, Nancey, S, additional, Bouguen, G, additional, Allez, M, additional, Serrero, M, additional, Chupin, A, additional, Caillo, L, additional, Viennot, S, additional, Blanc, P, additional, Reimund, J M, additional, Laharie, D, additional, Olivier, R, additional, Laurent, P B, additional, Dib, N, additional, De Maissin, A, additional, Montuclard, C, additional, Trang-Poisson, C, additional, Gaillot, G, additional, Bressollette-Bodin, C, additional, Berthome, M, additional, Burel, M, additional, Vavasseur, F, additional, Bourreille, A, additional, and Le Berre, C, additional

Published
2022
Full Text
View/download PDF

16. OP01 Withdrawal of infliximab or anti-metabolite therapy in Crohn’s Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE)

Author

Louis J, E, primary, Resche-Rigon, M, additional, Laharie, D, additional, Satsangi, J, additional, Ding, N, additional, Preiss, J, additional, D’Haens, G, additional, Picon, L, additional, Bossuyt, P, additional, Vuitton, L, additional, Irving, P, additional, Bouhnik, Y, additional, Viennot, S, additional, Lamb, C, additional, Pollock, R, additional, Baert, F, additional, Nachury, M, additional, Mathurin, F, additional, Gilletta, C, additional, Colombel, J F, additional, and Hertervig, E, additional

Published
2022
Full Text
View/download PDF

17. P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study

Author

Poullenot, F, primary, Amiot, A, additional, Nachury, M, additional, Viennot, S, additional, Altwegg, R, additional, Bouhnik, Y, additional, Abitbol, V, additional, Nancey, S, additional, Vuitton, L, additional, Peyrin-Biroulet, L, additional, Biron, A, additional, Fumery, M, additional, Picon, L, additional, Vidon, M, additional, Reenaers, C, additional, Serrero, M, additional, Savoye, G, additional, Beaugerie, L, additional, Rivière, P, additional, and Laharie, D, additional

Published
2022
Full Text
View/download PDF

18. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study

Author

Fumery, Mathurin, Filippi, J., Abitbol, V., Biron, A., Laharie, D., Serrero, M., Altwegg, R., Bouhnik, Y., Peyrinbiroulet, L., Gilletta, C., Roblin, X., Chambrun, G. Pineton, Vuitton, L., Bourrier, A., Nancey, S., Gornet, J. M., Nahon, S., Bouguen, G., Viennot, S., Pariente, B., Amiot, A., Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Clichy, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Pasteur [Nice] (CHU), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpital Claude Huriez [Lille], CHU Lille, and CHU Henri Mondor [Créteil]

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; Background: Phase III trials have demonstrated the efficacy and safety of ustekinumab in moderate-to-severe ulcerative colitis (UC), but no real-life long-term data is currently available. Methods: From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included. Patients were evaluated at week 52. Remission was defined by a partial Mayo Clinic score ≤ 2. The aim of the present study was to assess long-term effectiveness and safety of usteki numab in UC. Results: 103 UC patients (62 men; mean age: 41.2 ± 16.2 years; 52% pancolitis E3) were included in 21 centres. History of immunomodulator, anti-TNF and vedolizumab therapies was noted in 84.5%, 99.0% and 85.4% of the cases, respectively. At week 54, 44 (43%) patients discontinued ustekinumab, for lack of efficacy (n=41), pregnancy (n=1), persistence of eczematiform lesions (n=1) or personal decision (n=1). Cumulative probabilities of ustekinumab persistence were 96.1%, 81.6%, 71.7%, and 58.4% after 3, 6, 9, and 12 months, respectively. In multivariate analysis, a CRP>5 mg/L at week 0 (OR=2.91, CI95%[1.15–7.36]; p=0.02) and concomitant steroids at week 0 (OR=3.05, CI95%[1.30–7.14]; p=0.01) were significantly associated with ustekinumab discontinuation within one year. The overall rate of steroid-free clinical remission at week 52 was 32% of whom 71% had null rectal bleeding and stool frequency Downloaded from https://academic.oup.com/ecco-jcc/article/15/Supplement_1/S486/6286779 by guest on 03 February 2022 Abstracts of the 16th Congress of ECCO - European Crohn's and Colitis Organisation S487 subscores. Ten patients (9.7%) underwent colectomy within a median of 6.7 [4.3–10.6] months. Adverse events were observed in 15 (16.9%) patients, of whom 4 (4.5%) had severe adverse events including three patients with exacerbation of UC leading to hospitalization, and a 62 years-old men who died from a myocardial infarction four months after ustekinumab initiation. Conclusion: In this real-world cohort study that included patients with refractory ulcerative colitis to multiple therapies, more than one-half of patients were still treated by ustekinumab and one-third were in steroid-free clinical remission, after 52 weeks.

Published
2021
Full Text
View/download PDF

21. P272 Tofacitinib as salvage therapy for patients hospitalized with refractory severe active ulcerative colitis: a GETAID multicenter prospective/retrospective cohort

Author

Uzzan, M, primary, Bresteau, C, additional, Laharie, D, additional, Stefanescu, C, additional, Carbonnel, F, additional, Serrero, M, additional, Viennot, S, additional, Nachury, M, additional, Amiot, A, additional, Altwegg, R, additional, Picon, L, additional, Nahon, S, additional, Vuitton, L, additional, Ah Soune, P, additional, Kirchgesner, J, additional, Peyrin-Biroulet, L, additional, and Bouhnik, Y, additional

Published
2021
Full Text
View/download PDF

22. P504 Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study

Author

Fumery, M, primary, Filippi, J, additional, Abitbol, V, additional, Biron, A, additional, Laharie, D, additional, Serrero, M, additional, Altwegg, R, additional, Bouhnik, Y, additional, Peyrinbiroulet, L, additional, Gilletta, C, additional, Roblin, X, additional, Pineton de Chambrun, G, additional, Vuitton, L, additional, Bourrier, A, additional, Nancey, S, additional, Gornet, J M, additional, Nahon, S, additional, Bouguen, G, additional, Viennot, S, additional, Pariente, B, additional, and Amiot, A, additional

Published
2021
Full Text
View/download PDF

26. Validation of IBD-disk for the assessment of daily-life burden of patients with inflammatory bowel disease

Author

Tadbiri, S., Nachury, M., Bouhnik, Y., Serrero, M., Jerome, F., Roblin, X., Bourrier, A., Bouguen, G., Franchimont, D., Savoye, G., Buisson, A., Louis, E., Nancey, S., Abtibol, V., Reimund, J. M., Dewitt, O., Vuitton, L., Matthieu, N., Peyrin-Biroulet, L., Gilletta, C., Allez, M., Viennot, S., Bourreille, A., Dib, N., Brixi, H., Boualit, M., Plastaras, L., Altwegg, R., Fumery, Mathurin, Caillo, L., Laharie, D., Amiot, A., Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'Hépato-gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Pontchaillou [Rennes], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Clermont-Ferrand, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre hospitalier [Valenciennes, Nord], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

27. No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy

Author

Wils, P., Seksik, P., Stefanescu, C., Nancey, S., Allez, M., Laharie, D., de Chambrun, G. Pineton, Altwegg, R., Gilletta, C., Vuitton, L., Viennot, S., Serrero, M., Fumery, Mathurin, Savoye, G., Collins, M., Goutorbe, F., Brixi, H., Bouguen, G., Tavernier, N., Boualit, M., Amiot, A., Abitbol, V., Pariente, B., Grp, Getaid, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Beaujon, Assistance Publique - Hôpitaux de Paris, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Physics, University of Surrey, University of Surrey (UNIS), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Hospitalier de la Côte Basque, CHU Pontchaillou [Rennes], Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada, Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France, Centre hospitalier [Valenciennes, Nord], Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille, and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

28. Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study

Author

Amiot, A., Vered, A., Filippi, J., Cadiot, G., Laharie, D., Melanie, S., Altwegg, R., Bouhnik, Y., Peyrin-Biroulet, L., Gilletta, C., Roblin, X., Chambrun, G. Pineton, Vuitton, L., Bourrier, A., Nancey, S., Gornet, J. M., Nahon, S., Bouguen, G., Viennot, S., Benjamin, P., Fumery, Mathurin, DESSAIVRE, Louise, Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Universitaire de Reims (CHU Reims), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'Hépato-gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital Pasteur [Nice] (CHU), CHU Pontchaillou [Rennes], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), and Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

29. Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)

Author

Buisson, A., Fumery, Mathurin, Serrero, M., Orsat, L., Nancey, S., Riviere, P., Altwegg, R., Peyrin-Biroulet, L., Nachury, M., Hebuterne, X., Gilletta, C., Flamant, M., Viennot, S., Bouguen, G., Amiot, A., Mathieu, S., Vuitton, L., Plastaras, L., Bourreille, A., Caillo, L., Goutorbe, F., Chambrun, G. Pineton, Attar, A., Roblin, X., Pereira, B., Pariente, B., and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio]
Published
2020

30. Efficacy of vedolizumab in perianal Crohn's disease: the BioLAP multi-centre observational study

Author

Biron, C., Seksik, P., Nachury, M., Nancey, S., Bouhnik, Y., Serrero, M., Armengol-Debeir, L., Buisson, Anthony, Minh, M. -L. Tran, Zallot, C., Fumery, Mathurin, Bouguen, G., Abitbol, V., Viennot, S., Chanteloup, E., Rajca, S., Dib, N., Peyrin-Biroulet, L., Vuitton, L., Service de Gastro-Entérologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Claude Huriez [Lille], CHU Lille, Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), CHU Clermont-Ferrand, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gastro entérologie [Hôpital Paris Saint-Joseph], Hôpital Paris Saint-Joseph, Hôpital Louis Mourier - AP-HP [Colombes], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), and European Crohn’s and Colitis Organisation

Subjects
[SDV]Life Sciences [q-bio], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019
Full Text
View/download PDF

31. The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study

Author

Amiot, A., Serrero, M., Peyrin-Biroulet, L., Filippi, J., Pariente, B., Roblin, X., Buisson, Anthony, Stefanescu, C., Trang-Poisson, C., Altwegg, R., Marteau, P., Vaysse, T., Bourrier, A., Nancey, S., Laharie, D., Allez, M., Savoye, G., Moreau, J., Vuitton, L., Viennot, S., Aubourg, A., Pelletier, A. -L., Bouguen, G., Abitbol, V., Fumery, Mathurin, Gagniere, C., Bouhnik, Y., CHU Henri Mondor [Créteil], Service de Gastro-entérologie [CHU Hôpital Nord - Marseille], Hôpital Nord [CHU - APHM]-Assistance publique Hôpitaux de Marseille (APHM), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastro-entérologie et Hépatologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), CHU Clermont-Ferrand, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Hépato-gastro-entérologie [APHP Kremlin-Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), STMicroelectronics [Crolles] (ST-CROLLES), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, European Crohn’s and Colitis Organisation, CHU Henri Mondor, Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019
Full Text
View/download PDF

32. Efficacy of ustekinumab in perianal Crohn's disease: the BioLAP multi-centre observational study

Author

Biron, C., Seksik, P., Nachury, M., Bouhnik, Y., Amiot, A., Viennot, S., Serrero, M., Fumery, Mathurin, Allez, M., Siproudhis, L., Buisson, A., Chambrun, G. Pineton, Abitbol, V., Nancey, S., Caillo, L., Plastaras, L., Armengol-Debeir, L., Chanteloup, E., Simon, M., Dib, N., Rajca, S., Amil, M., Peyrin-Biroulet, L., Vuitton, L., Service de Gastro-Entérologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de gastro-entérologie [Henri Mondor AP-HP, Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gastro-entérologie [CHU Hôpital Nord - Marseille], Hôpital Nord [CHU - APHM]-Assistance publique Hôpitaux de Marseille (APHM), Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Hôpital pasteur [Colmar], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Gastro entérologie [Hôpital Paris Saint-Joseph], Hôpital Paris Saint-Joseph, Institut mutualiste Monsouris (IMM), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Louis Mourier - AP-HP [Colombes], Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), and European Crohn’s and Colitis Organisation

Subjects
[SDV]Life Sciences [q-bio], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019
Full Text
View/download PDF

33. Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis

Author

Lair-Mehiri, L., Stefanescu, C., Vaysse, T., Laharie, D., Roblin, X., Rosa, I., Treton, X., Abitbol, V., Amiot, A., Bouguen, G., Dib, N., Fumery, Mathurin, Pariente, B., Carbonnel, F., Peryn-Biroulet, L., Simon, M., Viennot, S., Bouhnik, y., Beaujon, Assistance Publique - Hôpitaux de Paris, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Centre Hospitalier Intercommunal de Créteil (CHIC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], CHU Henri Mondor, Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Hôpital Claude Huriez [Lille], CHU Lille, Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Laboratoire de Chimie Physique - Matière et Rayonnement (LCPMR), Institut de Chimie du CNRS (INC)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019
Full Text
View/download PDF

34. Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study

Author

Pineton de Chambrun, G., Pariente, B., Seksik, P., Altwegg, R., Vuitton, L., Stefasnescu, C, Nancey, S., Aubourg, A, Serrero, M, Peyrin-Biroulet, L., Filippi, J., Viennot, S, Abitbol, V., Boualit, M., Boureille, A, Moreau, J., Buisson, A., Roblin, X., Nachury, M., Zappa, M., Lambert, J., Bouhnik, Y., Study Group, Getaid-Mica, Herrada, Anthony, Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Département d'hépato-gastro-entérologie [Hôpital Trousseau : CHRU Tours], CHU Trousseau [APHP], Hôpital Nord [CHU - APHM], Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier [Valenciennes, Nord], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Clermont-Ferrand, Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Service de biostatistiques et information médicale [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université de Montpellier (UM)-CHU Saint-Eloi, Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-CHU Trousseau [APHP], CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)-CHU Trousseau [APHP], and Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]

Subjects
0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, 03 medical and health sciences, 0302 clinical medicine, medicine, Adalimumab, Abscess, Crohn's disease, business.industry, General surgery, Gastroenterology, Abdominal Abscess, Intra-abdominal Abscess, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, General Medicine, Bowel resection, medicine.disease, Crohn's Disease Activity Index, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, 3. Good health, 030104 developmental biology, 030211 gastroenterology & hepatology, business, Cohort study, medicine.drug
Abstract

International audience; doi:10.1093/ecco-jcc/jjy222 Abstract P528 from the 'Poster presentations' section of the main abstract book has been withdrawn and re-inserted as DOP63 in the 'Late-breaking abstracts' section.

Published
2019
Full Text
View/download PDF

35. P719 Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study

Author

Amiot, A, primary, Vered, A, additional, Filippi, J, additional, Cadiot, G, additional, Laharie, D, additional, Melanie, S, additional, Altwegg, R, additional, Bouhnik, Y, additional, Peyrin-biroulet, L, additional, Gilletta, C, additional, Roblin, X, additional, Pineton de chambrun, G, additional, Vuitton, L, additional, Bourrier, A, additional, Nancey, S, additional, Gornet, J M, additional, Nahon, S, additional, Bouguen, G, additional, Viennot, S, additional, Benjamin, P, additional, and Fumery, M, additional

Published
2020
Full Text
View/download PDF

36. P355 Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)

Author

Buisson, A, primary, Fumery, M, additional, Serrero, M, additional, Orsat, L, additional, Nancey, S, additional, Rivière, P, additional, Altwegg, R, additional, Peyrin-Biroulet, L, additional, Nachury, M, additional, Hébuterne, X, additional, Gilletta, C, additional, Flamant, M, additional, Viennot, S, additional, Bouguen, G, additional, Amiot, A, additional, Mathieu, S, additional, Vuitton, L, additional, Plastaras, L, additional, Bourreille, A, additional, Caillo, L, additional, Goutorbe, F, additional, Pineton de Chambrun, G, additional, Attar, A, additional, Roblin, X, additional, Pereira, B, additional, and Pariente, B, additional

Published
2020
Full Text
View/download PDF

37. P447 No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy

Author

Wils, P, primary, Seksik, P, additional, Stefanescu, C, additional, Nancey, S, additional, Allez, M, additional, Laharie, D, additional, Pineton De Chambrun, G, additional, Altwegg, R, additional, Gilletta, C, additional, Vuitton, L, additional, Viennot, S, additional, Serrero, M, additional, Fumery, M, additional, Savoye, G, additional, Collins, M, additional, Goutorbe, F, additional, Brixi, H, additional, Bouguen, G, additional, Tavernier, N, additional, Boualit, M, additional, Amiot, A, additional, Abitbol, V, additional, and Pariente, B, additional

Published
2020
Full Text
View/download PDF

38. P665 Which second-line biologic after anti-TNF failure during Crohn’s disease: Ustekinumab or vedolizumab, a multicentre retrospective study

Author

Rayer, C, primary, Roblin, X, additional, Laharie, D, additional, Caron, B, additional, Flamant, M, additional, Dewitte, M, additional, Fumery, M, additional, Viennot, S, additional, Bourreille, A, additional, Pariente, B, additional, Siproudhis, L, additional, Peyrin-Biroulet, L, additional, and Bouguen, G, additional

Published
2020
Full Text
View/download PDF

39. P248 Validation of IBD-disk for the assessment of daily-life burden of patients with inflammatory bowel disease

Author

Tadbiri, S, primary, Nachury, M, additional, Bouhnik, Y, additional, Serrero, M, additional, Jerome, F, additional, Roblin, X, additional, Bourrier, A, additional, Bouguen, G, additional, Franchimont, D, additional, Savoye, G, additional, Buisson, A, additional, Louis, E, additional, Nancey, S, additional, Abtibol, V, additional, Reimund, J M, additional, DeWitt, O, additional, Vuitton, L, additional, Matthieu, N, additional, Peyrin-Biroulet, L, additional, Gilletta, C, additional, Allez, M, additional, Viennot, S, additional, Bourreille, A, additional, Dib, N, additional, Brixi, H, additional, Boualit, M, additional, Plastaras, L, additional, Altwegg, R, additional, Fumery, M, additional, Caillo, L, additional, Laharie, D, additional, and Amiot, A, additional

Published
2020
Full Text
View/download PDF

40. Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID

Author

Caron, B., Peyrin-Biroulet, L., Nachury, M., Bouhnik, Y., Seksik, P., Bouguen, G., Caillo, L., Laharie, D., Carbonnel, F., Altwegg, R., Reenaers, C., Serrero, M., Boureille, A., Nancey, S., Filippi, J., Abitbol, V., Savoye, G., Vuitton, L., Viennot, S., Fumery, Mathurin, Reymond, M., Bronowicki, J. P., Reimund, J. -M., Amiot, A., Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Department of Gastroenterology and Hepatology, University Medical Centre, Centre Hospitalier Universitaire de Nice (CHU Nice), Laboratoire GlaxoSmithKline [ Marly-le-Roi], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Departement de Gastroentérologie, Hôpital de Hautepierre [Strasbourg], CHU Henri Mondor [Créteil], Institut des Sciences de la Terre de Paris (iSTeP), Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Hôpital Charles Nicolle [Rouen]-CHU Rouen, CHU Henri Mondor, and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

41. Efficacy of anti-TNF treatment in patients with refractory ulcerative proctitis: Results from a French retrospective multi-centre national cohort

Author

Chambrun, G. Pineton, Amiot, A., Bouguen, G., Viennot, S., Altwegg, R., Louis, E., Collins, M., Fumery, Mathurin, Poullenot, F., Armengol, L., Buisson, A., Abitbol, V., Bouhnik, Y., Laharie, D., Seksik, P., Nancey, S., Blanc, P., Nachury, M., Peyrin-Biroulet, L., CHU Henri Mondor [Créteil], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Department of Physics, University of Surrey, University of Surrey (UNIS), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, CHU Bordeaux [Bordeaux], Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Laboratoire GlaxoSmithKline [ Marly-le-Roi], Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Department of Gastroenterology and Hepatology, University Medical Centre, Station d'Expérimentation Régionale sur les Fruits et Légumes (SERFEL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

42. DOP78 Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multi-centre observational study

Author

Biron, C, primary, Seksik, P, additional, Nachury, M, additional, Nancey, S, additional, Bouhnik, Y, additional, Serrero, M, additional, Armengol-Debeir, L, additional, Buisson, A, additional, Tran Minh, M-L, additional, Zallot, C, additional, Fumery, M, additional, Bouguen, G, additional, Abitbol, V, additional, Viennot, S, additional, Chanteloup, E, additional, Rajca, S, additional, Dib, N, additional, Peyrin-Biroulet, L, additional, and Vuitton, L, additional

Published
2019
Full Text
View/download PDF

43. P711 The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study

Author

Amiot, A, primary, Serrero, M, additional, Peyrin-Biroulet, L, additional, Filippi, J, additional, Pariente, B, additional, Roblin, X, additional, Buisson, A, additional, Stefanescu, C, additional, Trang-Poisson, C, additional, Altwegg, R, additional, Marteau, P, additional, Vaysse, T, additional, Bourrier, A, additional, Nancey, S, additional, Laharie, D, additional, Allez, M, additional, Savoye, G, additional, Moreau, J, additional, Vuitton, L, additional, Viennot, S, additional, Aubourg, A, additional, Pelletier, A-L, additional, Bouguen, G, additional, Abitbol, V, additional, Fumery, M, additional, Gagniere, C, additional, and Bouhnik, Y, additional

Published
2019
Full Text
View/download PDF

44. OP24 Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn’s disease

Author

Fumery, M, primary, Peyrin-biroulet, L, additional, Nancey, S, additional, Altwegg, R, additional, Veyrard, P, additional, Bouguen, G, additional, Viennot, S, additional, Poullenot, F, additional, Filippi, J, additional, Buisson, A, additional, Bozon, A, additional, Gilletta, C, additional, Brazier, F, additional, Pouillon, L, additional, Flourié, B, additional, Boivineau, L, additional, Siproudhis, L, additional, Laharie, D, additional, Roblin, X, additional, and Treton, X, additional

Published
2019
Full Text
View/download PDF

45. DOP74 Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study

Author

Biron, C, primary, Seksik, P, additional, Nachury, M, additional, Bouhnik, Y, additional, Amiot, A, additional, Viennot, S, additional, Serrero, M, additional, Fumery, M, additional, Allez, M, additional, Siproudhis, L, additional, Buisson, A, additional, Pineton de Chambrun, G, additional, Abitbol, V, additional, Nancey, S, additional, Caillo, L, additional, Plastaras, L, additional, Armengol-Debeir, L, additional, Chanteloup, E, additional, Simon, M, additional, Dib, N, additional, Rajca, S, additional, Amil, M, additional, Peyrin-Biroulet, L, additional, and Vuitton, L, additional

Published
2019
Full Text
View/download PDF

46. P323 Prognostic factors for long-term adalimumab treatment

Author

Fumery, M, primary, Duveau, N, additional, Perignon, C, additional, Lepeut, G, additional, Lahaye, A, additional, Le Baut, G, additional, Roussillon, C, additional, Yzet, C, additional, Loreau, J, additional, Wils, P, additional, Nachury, M, additional, Pariente, B, additional, and Viennot, S, additional

Published
2019
Full Text
View/download PDF

47. P286 Bariatric surgery in inflammatory bowel disease: outcome and safety from a GETAID registry population

Author

Reenaers, C, primary, Nachury, M, additional, Stefanescu, C, additional, Pineton de Chambrun, G, additional, Laharie, D, additional, Boileve, J, additional, Viennot, S, additional, Peyrin-Biroulet, L, additional, Roblin, X, additional, Grimaud, J-C, additional, Bouguen, G, additional, Nahon, S, additional, Goutorbe, F, additional, and Coffin, B, additional

Published
2019
Full Text
View/download PDF

48. P715 Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis

Author

Lair-Mehiri, L, primary, Stefanescu, C, additional, Vaysse, T, additional, Laharie, D, additional, Roblin, X, additional, Rosa, I, additional, Treton, X, additional, Abitbol, V, additional, Amiot, A, additional, Bouguen, G, additional, Dib, N, additional, Fumery, M, additional, Pariente, B, additional, Carbonnel, F, additional, Peryn-Biroulet, L, additional, Simon, M, additional, Viennot, S, additional, and Bouhnik, Y, additional

Published
2019
Full Text
View/download PDF

49. Autoimmune pancreatitis associated with inflammatory bowel disease: a multicentric study of the GETAID

Author

Lorenzo, D., Maire, F., Stefanescu, C., Gornet, J. M., Seksik, P., Grimaud, J. C., Bournet, B., Marteau, P., Amiot, Audrey, Laharie, D., Trang, C., Coffin, B., Bellaiche, G., Cadiot, G., Reenaers, C., Racine, A., Viennot, S., Pauwels, A., Bouguen, G., Savoye, G., Pelletier, A. L., de Pineton Chambrun, G., Lahmek, P., Nahon, S., Abitbol, V, Service de gastroentérologie, MICI et assistance nutritive, pôle des maladies de l’appareil digestif, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Géoazur (GEOAZUR 6526), Institut de Recherche pour le Développement (IRD)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Hôpital Robert Debré, Service d'Hépato-gastroentérologie, 51092 Reims, France, affiliation inconnue, Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), ONERA - The French Aerospace Lab [Palaiseau], ONERA-Université Paris Saclay (COmUE), Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Recherche pour le Développement (IRD)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; Meeting Abstract: P256

Published
2016
Full Text
View/download PDF

50. A negative screening does not eliminate tuberculosis risk under anti-TNF treatment in inflammatory bowel disease: a descriptive study

Author

Abitbol, Y., Laharie, D., Cosnes, J., Allez, M., Nancey, S., Amiot, Audrey, Aubourg, A., Fumery, Mathurin, Altwegg, R., Michetti, P., Chanteloup, E., Seksik, P., Abitbol, V., Baudry, C., Flamant, M., Bouguen, G., Stefanescu, C., Bourrier, A., Bommelaer, G., Dib, N., Bigard, M. A., Viennot, S., Hébuterne, X., Gornet, J. M., Marteau, P., Bouhnik, Y., Nahon, S, Service de Gastroentérologie et nutrition [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d’hépatogastroenterologie, CHU Amiens-Picardie, Département de gastroentérologie, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Service de gastroentérologie, MICI et assistance nutritive, pôle des maladies de l’appareil digestif, Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nice (CHU de Nice), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), AP-HP, Hôpital Lariboisière, Hôpital Lariboisière-Fernand-Widal [APHP], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Nice (CHU Nice), and Université Nice Sophia Antipolis (1965 - 2019) (UNS)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; Meeting abstract Sa1949

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results